Patent Landscape Analysis: US Patent 8,759,350 (Aripiprazole + Citalopram/Escitalopram SSRIs) and Its Claim Scope
US Patent 8,759,350 protects pharmaceutical compositions and treatment methods that combine aripiprazole with at least one serotonin reuptake inhibitor (SSRI) from citalopram and/or escitalopram (and salts). The claims cover (1) combination formulations, (2) utility across a broad depression and neuropsychiatric symptom set, (3) a specific aripiprazole solid-state variant (“anhydrous aripiprazole crystals B”), and (4) administration/method claims that track the composition claims.
The key practical consequence is that the patent estate is aimed at combination product manufacturing and use, not at a single fixed dose regimen. The broadest independent claim structure is “aripiprazole + SSRI (citalopram/escitalopram, salts),” which raises infringement risk for generic or branded entrants that sell or use these combinations in the claimed therapeutic contexts.
What does US 8,759,350 claim for aripiprazole plus citalopram or escitalopram?
Direct answer (claim scope): US 8,759,350 covers (i) pharmaceutical compositions containing aripiprazole plus an SSRI selected from citalopram and/or escitalopram (including salts), and (ii) methods of treating mood disorders in a patient by administering that combination, with additional narrower coverage for anhydrous aripiprazole crystals B, pharmaceutically acceptable carriers, and (in dependent form) a 1 to 70 wt% aripiprazole:SSRI combination ratio.
Which claims are composition claims vs method claims?
Is the SSRI scope “single-agent only” or “combo SSRI”?
The claims are written as “at least one serotonin reuptake inhibitor” selected from:
- citalopram and/or escitalopram, including salts.
This reads as allowing:
- a formulation containing aripiprazole + citalopram (Claim 2)
- aripiprazole + escitalopram (Claim 3)
- or aripiprazole + either or both citalopram and escitalopram (Claim 1), because Claim 1 expressly covers at least one from the group.
What is the aripiprazole solid-state limiter doing (crystals B)?
Claims 4 and 12 narrow coverage to combinations where aripiprazole is specifically “anhydrous aripiprazole crystals B.”
For infringement strategy, this matters because:
- If an accused product uses a different aripiprazole form (hydrate, amorphous, different polymorph), Claims 4/12 may not read.
- Claims 1–3 and 6–11 do not include the crystals B limitation, so combination formulations still risk infringement regardless of aripiprazole polymorph unless the defendant can carve around claims without meeting the “crystals B” requirement only for those narrower dependents.
How broad are the therapeutic indications covered by US 8,759,350?
Direct answer: The indication set is broader than “MDD alone.” It includes a spectrum of depression-like mood disorders across dementias, Parkinson’s, cerebrovascular-associated mood disorders, post–head injury mood disorders, and bipolar depressive phase, plus depression “with psychotic episodes.”
Therapeutic area mapping by claim
- Depression/MDD: Claims 6, 14
- MDD with dementia with depressive symptoms: Claims 7, 15
- Expanded mood disorder list: Claim 8 and repeated in 9–11 and 16, including:
- major depressive disorder (MDD)
- endogenous depression
- melancholia
- depression with psychotic episodes
- bipolar disorder with depressive phase
- refractory depression
- dementia of the Alzheimer’s type with depressive symptoms
- Parkinson’s disease with depressive symptoms
- senile dementia
- mood disorder associated with cerebral blood vessels
- mood disorder following head injury
Practical implication for infringement and label design
If a product is marketed for the claimed combinations, method claim risk is highest when:
- the product is prescribed in the claimed patient populations; and/or
- the FDA labeling, promotional materials, and real-world prescribing are consistent with these indications.
Because method claims are “treatment of mood disorders” by administering the combo, label indications are not the only source of proof, but they strongly influence litigation outcomes in US patent enforcement.
What exact combination does US 8,759,350 cover, and how does it differ across independent claims?
Direct answer: Independent composition claim 1 is the broadest because it covers aripiprazole + at least one SSRI from both citalopram and escitalopram families. Dependent composition claims split into narrower SSRI-specific versions.
Claim-by-claim combination boundaries
| Claim |
SSRI scope |
Aripiprazole requirement |
Extra limits |
| 1 |
citalopram +/or escitalopram + salts |
aripiprazole (no polymorph limit) |
none |
| 2 |
citalopram + salts |
aripiprazole (no polymorph limit) |
none |
| 3 |
escitalopram + a salt |
aripiprazole (no polymorph limit) |
none (still lacks crystals B) |
| 4 |
same as 1–3 |
anhydrous aripiprazole crystals B |
crystals B limiter |
| 5 |
same as 1–3 |
aripiprazole |
pharmaceutically acceptable carrier |
| 18 |
same as 1–3 |
aripiprazole + SSRI |
“amount … is 1 to 70 parts by weight” of total composition |
Dose and ratio coverage: does it look like a fixed-dose patent?
Claim 18 includes a compositional ratio in “parts by weight,” but the range is wide:
- 1 to 70 parts by weight of the total composition (as written)
This kind of claim is typically designed to cover a wide dosing spectrum and reduce easy design-arounds by changing dose strength.
How strong is the patent estate for aripiprazole + SSRI combinations beyond US 8,759,350?
US 8,759,350 is a combination/formulation and method-of-use patent. In US practice, combination patents frequently sit in a landscape that also includes:
- earlier aripiprazole polymorph/form IP,
- later fixed-dose combination formulation patents,
- and broad antidepressant augmentation or “atypical antipsychotic + SSRI” treatment patents.
However, a complete landscape requires specific publication data (application number, assignee, priority date, family members, and prosecution history). That information is not provided in the prompt, so a reliable, numbered citation-based map of related US patents (and which ones overlap the claim elements) cannot be produced.
What can be concluded from the claim text alone: US 8,759,350 targets at least four infringement hooks:
- selling a composition with aripiprazole + citalopram/escitalopram;
- manufacturing such a composition (composition claims are generally product-by-process neutral for “composition comprising” language);
- treating the covered mood disorders via administration of that combination (method claims);
- using anhydrous aripiprazole crystals B specifically (dependent composition/method).
What patent scope is most vulnerable to design-arounds: crystals B, carriers, or the SSRI pairing?
Direct answer: The SSRI pairing (citalopram/escitalopram) and aripiprazole combination are the hardest to design around; the polymorph (“anhydrous crystals B”) is the easiest because it is an explicit structural limitation limited to dependent claims.
1) Switching from citalopram/escitalopram to another SSRI
The independent claims are limited to:
- citalopram and escitalopram (and salts).
A switch to sertraline, fluoxetine, paroxetine, fluvoxamine, etc. would likely avoid the literal SSRI element. (A court could still consider doctrine of equivalents, but literal scope is narrow by drug identity.)
2) Changing aripiprazole polymorph
If a product uses aripiprazole that is not “anhydrous aripiprazole crystals B,” it may avoid dependent claims 4 and 12, but not the broader independent claims 1–3 and associated method claims 9–11 unless those also incorporate crystals B (they do not).
3) Reformulating carriers/excipients
Carrier coverage is broad and generic:
- Claim 5 broadly requires a pharmaceutically acceptable carrier.
- Claim 17 lists typical excipient classes (fillers, binders, disintegrants, surfactants, lubricants).
Most solid oral formulations will satisfy this, so carrier changes are not a strong design-around path.
4) Altering composition ratios
Claim 18 provides a wide numeric range. A strategy that changes ratios may still fall within the claim language depending on how the “parts by weight” is interpreted for the accused formulation.
How would generic entry risk be assessed for aripiprazole + citalopram/escitalopram combinations?
Direct answer: Risk is principally driven by whether a generic files for a combination and whether it is marketed or used for the claimed indications. If the generic’s ANDA/505(b)(2) produces a product with the same combination and is labeled for the same mood-disorder indications, infringement risk on composition and method claims is high.
Key ANDA/505(b)(2) risk factors
- Is the proposed product a true combination with the claimed SSRIs? (citalopram and/or escitalopram, salts)
- Does the product have labeling for depression-related indications included in Claims 6–8 and 14–16?
- Does the product use aripiprazole polymorph “anhydrous crystals B”? (only relevant to dependent claims)
- Does the generic attempt to argue non-infringement by changing only excipients or dose form? Likely insufficient due to carrier language and broad combination coverage.
Does US 8,759,350 map cleanly to Orange Book-type listing risk?
The prompt does not provide the patent number’s Orange Book listing entries (drug product, NDA/BLA, expiration, exclusivity codes, or whether listed for specific strengths). Without that mapping, no definitive Orange Book status can be stated.
Claim text does show the patent is well-suited for Orange Book listing because it is a composition + method-of-use patent that typically corresponds to listed drug products intended for depression/MDD and related disorders.
What does US 8,759,350 imply about FDA regulatory strategy for combination products?
Even without the FDA regulatory file details, the claim set implies FDA positioning issues:
- A combination product’s regulatory label and clinical claims must avoid aligning with method claims when attempting to reduce exposure.
- If the product is developed as a fixed-dose combination versus a co-packaged or concurrent administration, infringement analysis can differ, but the claims are drafted to cover a “pharmaceutical composition comprising” the two actives, so fixed-dose is most exposed.
What settlement or litigation outcomes are expected from US 8,759,350’s claim style?
No litigation docket information is included in the prompt. A case-by-case prediction is not supportable without:
- enforcement history,
- PLR/PRB events,
- assignments,
- and district-level filings.
From claim style alone, typical dispute points would include:
- whether the accused product contains aripiprazole + citalopram/escitalopram (salts) in a single composition;
- whether the accused product is used for the claimed mood disorders;
- and, for dependent claims, whether aripiprazole is anhydrous crystals B.
US 8,759,350 claim chart (element-by-element) for infringement screening
| Claim element |
What must be present |
Straightforward screening artifact |
| aripiprazole (a) |
Active is aripiprazole |
product label/CMC spec; API identity |
| SSRI (b) is citalopram/escitalopram (and salts) |
Active is citalopram and/or escitalopram (salt-inclusive) |
drug label/CMC; salt form |
| “pharmaceutical composition” |
Formulation contains both actives in a single composition |
dosage form and formulation |
| pharmaceutically acceptable carrier (Claim 5/13/17) |
Standard excipients |
formulation table |
| treatment of specified mood disorders |
Patient population use for listed conditions |
label indications; prescribing evidence |
| aripiprazole crystals B (Claim 4/12) |
Solid-state identity |
XRPD/DSC polymorph testing, certificates |
Key takeaways
- US 8,759,350 protects fixed combination pharmaceutical compositions and use of aripiprazole + citalopram/escitalopram (salts included), spanning a broad depression and neuropsychiatric mood-disorder indication set.
- The most durable infringement hook is the drug pairing in independent composition and method claims (Claims 1, 2, 3, and methods 9–11).
- The “anhydrous aripiprazole crystals B” limitation applies only to dependent claims (4 and 12), making it a narrower vulnerability point for crystallographic design-around.
- Carrier and excipient claims are broad (Claims 5 and 17), so formulation-only changes usually do not eliminate infringement exposure.
- The range in Claim 18 indicates the patent is meant to cover multiple dose strengths rather than a single fixed ratio.
FAQs
1) What combinations of SSRIs with aripiprazole does US 8,759,350 cover?
It covers citalopram and/or escitalopram (including salts), paired with aripiprazole.
2) Does US 8,759,350 require aripiprazole “anhydrous crystals B” to infringe?
No. “anhydrous aripiprazole crystals B” is required only for dependent claims 4 and 12.
3) Are dementia, Parkinson’s disease, and bipolar depressive phase included in the method claims?
Yes. The method claims incorporate the full disorder list in Claims 8 and 16, including Alzheimer’s-type dementia with depressive symptoms, Parkinson’s disease with depressive symptoms, and bipolar disorder with depressive phase.
4) Can a design-around use a different SSRI (not citalopram/escitalopram)?
The independent claims are limited to citalopram and/or escitalopram; using other SSRIs would avoid the specific SSRI element as written.
5) Does the patent protect only compositions or also methods of treatment?
Both. It includes composition claims (Claims 1–5, plus dependents) and method-of-treatment claims (Claims 6–16).
References
No source citations were provided or derivable from the prompt beyond the claim text itself.
